Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah C Gilbert

Showing results (171-180 of 215) with videos related to

Pageof 22
Sort By:
Wellcome Open Research|April 13, 2026
Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adultsDaniel Silman, Amy Flaxman, Mehreen Datoo, et al.
Nature Communications|June 24, 2018
Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectorsCésar López-Camacho, Peter Abbink, Rafael A Larocca, et al.
Plos One|February 25, 2012
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsSusanne H Sheehy, Christopher J A Duncan, Sean C Elias, et al.
The Journal of Infectious Diseases|November 9, 2018
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and SenegalNavin Venkatraman, Birahim Pierre Ndiaye, Georgina Bowyer, et al.
Infection and Immunity|December 12, 2007
Characterization of the fine specificity of bovine CD8 T-cell responses to defined antigens from the protozoan parasite Theileria parvaSimon P Graham, Roger Pellé, Mat Yamage, et al.
The Journal of Infectious Diseases|January 26, 2012
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vectorGeraldine A O'Hara, Christopher J A Duncan, Katie J Ewer, et al.
Nature Immunology|June 15, 2023
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19Paulina Kaplonek, Deniz Cizmeci, Gaurav Kwatra, et al.
Nature Communications|October 7, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in BrazilSue Ann Costa Clemens, Pedro M Folegatti, Katherine R W Emary, et al.
Nature Medicine|May 27, 2003
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humansSamuel J McConkey, William H H Reece, Vasee S Moorthy, et al.
Nature Communications|November 29, 2013
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisationKatie J Ewer, Geraldine A O'Hara, Christopher J A Duncan, et al.
Pageof 22

Showing results (171-180 of 215) with videos related to

Sort By:
Pageof 22
Wellcome Open Research|April 13, 2026
Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adultsDaniel Silman, Amy Flaxman, Mehreen Datoo, et al.
Nature Communications|June 24, 2018
Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectorsCésar López-Camacho, Peter Abbink, Rafael A Larocca, et al.
Plos One|February 25, 2012
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsSusanne H Sheehy, Christopher J A Duncan, Sean C Elias, et al.
The Journal of Infectious Diseases|November 9, 2018
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and SenegalNavin Venkatraman, Birahim Pierre Ndiaye, Georgina Bowyer, et al.
Infection and Immunity|December 12, 2007
Characterization of the fine specificity of bovine CD8 T-cell responses to defined antigens from the protozoan parasite Theileria parvaSimon P Graham, Roger Pellé, Mat Yamage, et al.
The Journal of Infectious Diseases|January 26, 2012
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vectorGeraldine A O'Hara, Christopher J A Duncan, Katie J Ewer, et al.
Nature Immunology|June 15, 2023
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19Paulina Kaplonek, Deniz Cizmeci, Gaurav Kwatra, et al.
Nature Communications|October 7, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in BrazilSue Ann Costa Clemens, Pedro M Folegatti, Katherine R W Emary, et al.
Nature Medicine|May 27, 2003
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humansSamuel J McConkey, William H H Reece, Vasee S Moorthy, et al.
Nature Communications|November 29, 2013
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisationKatie J Ewer, Geraldine A O'Hara, Christopher J A Duncan, et al.
Pageof 22